Trial Profile
Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study. Valore diagnostico incrementale di Florbetaben Imaging vs altri biomarcatori chiave per la Malattia di Alzheimer in pazienti con Deterioramento
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 27 Mar 2019 According to a Life Molecular Imaging, Piramal imaging changed its name to Life Molecular Imaging.
- 23 Feb 2018 New trial record